NasdaqGS - Nasdaq Real Time Price • USD
Syros Pharmaceuticals, Inc. (SYRS)
As of 10:28 AM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | -0.87 | -0.91 | -3.69 | -3.34 |
Low Estimate | -1.2 | -1.21 | -4.77 | -4.94 |
High Estimate | -0.69 | -0.69 | -2.8 | -1.05 |
Year Ago EPS | -0.85 | -1.3 | -5.81 | -3.69 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | 720k | 720k | 2.8M | 32.08M |
Low Estimate | -- | -- | -- | -- |
High Estimate | 1.8M | 1.8M | 7M | 130.4M |
Year Ago Sales | 2.95M | -- | 9.94M | 2.8M |
Sales Growth (year/est) | -75.60% | -- | -71.80% | 1,045.70% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -1.09 | -1.13 | -1.14 | -1.14 |
EPS Actual | -0.85 | -1.3 | -1.43 | -2.18 |
Difference | 0.24 | -0.17 | -0.29 | -1.04 |
Surprise % | 22.00% | -15.00% | -25.40% | -91.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.87 | -0.91 | -3.69 | -3.34 |
7 Days Ago | -0.87 | -0.91 | -3.69 | -3.34 |
30 Days Ago | -0.95 | -1.05 | -4.11 | -3.08 |
60 Days Ago | -0.95 | -1.05 | -4.11 | -3.08 |
90 Days Ago | -0.95 | -1.05 | -4.11 | -3.08 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 2 | 2 | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | SYRS | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -2.40% | -- | -- | 1.50% |
Next Qtr. | 30.00% | -- | -- | 12.10% |
Current Year | 36.50% | -- | -- | 4.40% |
Next Year | 9.50% | -- | -- | 13.20% |
Next 5 Years (per annum) | -- | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Piper Sandler: Overweight to Overweight | 4/3/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 10/3/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/9/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 5/11/2023 |
Maintains | JMP Securities: Market Outperform to Market Outperform | 5/11/2023 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
32.67
+0.60%
FGEN FibroGen, Inc.
1.0050
-1.47%
GLYC GlycoMimetics, Inc.
1.7200
+0.58%
KURA Kura Oncology, Inc.
19.25
+1.32%
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
ACIU AC Immune SA
2.4150
+5.46%
BDTX Black Diamond Therapeutics, Inc.
5.51
+7.83%
MCRB Seres Therapeutics, Inc.
0.7928
+6.75%
MAIA MAIA Biotechnology, Inc.
2.7199
+1.49%
STRO Sutro Biopharma, Inc.
3.4240
+0.12%